Ovid Therapeutics Inc. has provided an update on its neurotherapeutics pipeline, highlighting several clinical-stage programs targeting conditions driven by neural hyperexcitability. The company is advancing OV329, a GABA-aminotransferase inhibitor, for drug-resistant adult focal onset seizures. Phase 1 results showed a strong safety profile, positive biomarker outcomes, and inhibitory effects comparable to or exceeding those of vigabatrin. The next phase for OV329 includes a Phase 2a trial, with topline results expected in mid-2027. Ovid is also developing oral formulations in its potassium-chloride cotransporter 2 (KCC2) direct activator portfolio. OV4071 is being prepared for indications such as psychosis associated with Parkinson's disease, Lewy body dementia, and schizophrenia, with regulatory submissions and a proof-of-mechanism study planned. Another candidate, OV4041, is targeting generalized anxiety disorder and Rett syndrome, with late-stage preclinical development underway. The company reports a cash runway expected to fund operations into the second half of 2028. You can access the full presentation through the link below.